ProRx LLC – FDA 483, Sep 9, 2025

ProRx LLC, an outsourcing facility in Exton, PA, received an FDA Form 483 following an inspection conducted from September 9 to September 19, 2025. The inspection identified critical quality control and aseptic processing deficiencies. A primary issue was the consistent failure to thoroughly investigate unexplained discrepancies, including positive microbial growth in media fill vials and environmental monitoring samples from ISO 5, ISO 7, and ISO 8 areas. Despite these contamination events, operators were qualified, and numerous sterile drug product batches were released without adequate investigation or scientific justification, often based on an unsupported rationale of low pathogenicity, and without considering risks to immunocompromised patients. Investigations into mold detection on operators" fingertips were deemed inadequate, failing to assess comprehensive risk or extend to all affected batches. Additionally, investigation timeframes were exceeded without proper justification. A second significant observation highlighted inadequate environmental monitoring in aseptic processing areas, specifically noting that non-viable particle counting in ISO Class 5 areas was only performed during third-party certification, not routinely during aseptic production. These observations underscore a failure to adhere to good manufacturing practices for sterile products. ProRx LLC is expected to implement thorough corrective and preventive actions, including comprehensive investigations, improved microbial identification, and enhanced environmental monitoring, to ensure sterility assurance and product quality.